Magnetic resonance imaging and Crohn’s disease endoscopic index of severity: Correlations and concordance

Table 1 Characteristics of the patients before treatments

	All n = 104	Active n = 61	Inactive n = 43	P value
Gender (M/F)	59/45	36/25	23/20	0.230
Age	31.37 ± 9.56	27.5 ± 11.4	34.44 ± 5.37	0.650
Disease duration	3.5	3.9	3.3	0.550
Disease location
Rectum	0	0	0
Sigmoid/left colon	4	2	2
Transverse colon	14	7	7
Right colon	16	10	6
Ileum	70	42	28
Treatment regimen
Glucocorticoid	23	23	0
IFX	18	18	0
ADA	20	20	0
Edema	61	61	0	< 0.001
Reactive lymph nodes	25	16	9	0.311
Mucosal ulcer	49	38	11	< 0.001
Enhancement pattern	61	61	0	0.006
Morphological changes	31	12	19	0.023
Perienteric exudation	38	38	0	< 0.001
CRP (mg/L)	18.34 ± 8.45	25.12 ± 4.12	5.14 ± 0.98	< 0.001
ADC (mm2/s)	1.87 ± 0.471	1.598 ± 0.383	1.949 ± 0.431	0.001
Thickness (mm)	7.89 ± 3.23	9.23 ± 3.36	6.75 ± 2.49	0.001
tRCE (%)	78.34 ± 45.34	92.153 ± 101.34	40.592 ± 11.019	0.017
aRCE (%)	124.45 ± 61.11	181.46 ± 97.80	92.63 ± 45.48	< 0.001
pRCE (%)	254.21 ± 198.22	321.90 ± 231.03	201.32 ± 124.66	0.020
dRCE (%)	377.15 ± 223.21	466.18 ± 260.08	271.91 ± 209.66	0.002
MaRIA
tRCE	20.37 ± 3.42	26.18 ± 5.02	6.44 ± 1.03	< 0.001
aRCE	18.88 ± 4.11	28.40 ± 4.84	6.43 ± 2.74	< 0.001
pRCE	26.32 ± 2.89	35.09 ± 4.64	6.94 ± 2.58	< 0.001
dRCE	19.26 ± 3.21	36.81 ± 5.11	7.25 ± 2.32	0.001
CDEIS	8.15 ± 4.03	10.57 ± 3.02	3.46 ± 1.23	0.001

IFX: Infliximab; ADA: Adalimumab; CRP: C-reactive protein; ADC: Apparent diffusion coefficient; tRCE: Total relative contrast enhancement; aRCE: Arterial relative contrast enhancement; pRCE: Portal phase relative contrast enhancement; dRCE: Delay phase relative contrast enhancement; MaRIA: Magnetic resonance index of activity; CDEIS: Crohn’s disease endoscopic index of severity.